Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference
September 21, 2022 07:00 ET
|
Clene Inc.
Treatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomizationComparable survival benefits were also shown...
Clene to Present at Upcoming September Investor Conferences
August 30, 2022 07:00 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
August 15, 2022 07:00 ET
|
Clene Inc.
Topline results from the Phase 2 VISIONARY-MS clinical trial with CNM-Au8® met the primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional...
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
August 15, 2022 07:00 ET
|
Clene Inc.
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT...
Clene to Host VISIONARY-MS Results Call and Webcast on August 15
August 12, 2022 16:01 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
July 19, 2022 07:00 ET
|
Clene Inc.
SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
July 14, 2022 07:00 ET
|
Clene Inc.
As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths vs. 14 placebo deaths, HR=0.301, p=0.0143)CNM-Au8 treatment was...
Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
June 27, 2022 07:00 ET
|
Clene Inc.
SALT LAKE CITY, June 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Nanomedicine’s Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe
December 15, 2021 07:00 ET
|
Clene Inc.
Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022 SALT LAKE CITY, Dec. 15, 2021 (GLOBE...
Clene Nanomedicine’s Facility Improvement Project Receives $1 Million Grant Award from the Maryland Department of Housing and Community Development (DHCD)
December 13, 2021 07:00 ET
|
Clene Inc.
Clene Nanomedicine’s Maryland facility is among the projects and activities awarded fundingThe manufacturing expansion is in preparation for anticipated commercialization SALT LAKE CITY, Dec. 13,...